Cargando…
ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS
OBJECTIVE: To elucidate the relationship between disease stage in amyotrophic lateral sclerosis (ALS), as measured with the King's Clinical Staging System, and cognitive and behavioral change, measured with the Edinburgh Cognitive and Behavioural ALS Screen (ECAS). METHODS: A large multicenter...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6177274/ https://www.ncbi.nlm.nih.gov/pubmed/30209236 http://dx.doi.org/10.1212/WNL.0000000000006317 |
_version_ | 1783361840344989696 |
---|---|
author | Crockford, Christopher Newton, Judith Lonergan, Katie Chiwera, Theresa Booth, Tom Chandran, Siddharthan Colville, Shuna Heverin, Mark Mays, Iain Pal, Suvankar Pender, Niall Pinto-Grau, Marta Radakovic, Ratko Shaw, Christopher E. Stephenson, Laura Swingler, Robert Vajda, Alice Al-Chalabi, Ammar Hardiman, Orla Abrahams, Sharon |
author_facet | Crockford, Christopher Newton, Judith Lonergan, Katie Chiwera, Theresa Booth, Tom Chandran, Siddharthan Colville, Shuna Heverin, Mark Mays, Iain Pal, Suvankar Pender, Niall Pinto-Grau, Marta Radakovic, Ratko Shaw, Christopher E. Stephenson, Laura Swingler, Robert Vajda, Alice Al-Chalabi, Ammar Hardiman, Orla Abrahams, Sharon |
author_sort | Crockford, Christopher |
collection | PubMed |
description | OBJECTIVE: To elucidate the relationship between disease stage in amyotrophic lateral sclerosis (ALS), as measured with the King's Clinical Staging System, and cognitive and behavioral change, measured with the Edinburgh Cognitive and Behavioural ALS Screen (ECAS). METHODS: A large multicenter observational cohort of 161 cross-sectional patients with ALS and 80 healthy matched controls were recruited across 3 research sites (Dublin, Edinburgh, and London). Participants were administered the ECAS and categorized into independent groups based on their King's clinical disease stage at time of testing. RESULTS: Significant differences were observed between patients and controls on all subtests of the ECAS except for visuospatial functioning. A significant cross-sectional effect was observed across disease stages for ALS-specific functions (executive, language, letter fluency) and ECAS total score but not for ALS-nonspecific functions (memory, visuospatial). Rates of ALS-specific impairment and behavioral change were also related to disease stage. The relationship between cognitive function and disease stage may be due to letter fluency impairment, whereas higher rates of all behavioral domains were seen in later King's stage. The presence of bulbar signs, but not site of onset, was significantly related to ALS-specific, ECAS total, and behavioral scores. CONCLUSION: ALS-specific cognitive deficits and behavioral impairment are more frequent with more severe disease stage. By end-stage disease, only a small percentage of patients are free of neuropsychological impairment. The presence of bulbar symptoms exaggerates the differences observed between disease stages. These findings suggest that cognitive and behavioral change should be incorporated into ALS diagnostic criteria and should be included in future staging systems. |
format | Online Article Text |
id | pubmed-6177274 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-61772742018-10-11 ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS Crockford, Christopher Newton, Judith Lonergan, Katie Chiwera, Theresa Booth, Tom Chandran, Siddharthan Colville, Shuna Heverin, Mark Mays, Iain Pal, Suvankar Pender, Niall Pinto-Grau, Marta Radakovic, Ratko Shaw, Christopher E. Stephenson, Laura Swingler, Robert Vajda, Alice Al-Chalabi, Ammar Hardiman, Orla Abrahams, Sharon Neurology Article OBJECTIVE: To elucidate the relationship between disease stage in amyotrophic lateral sclerosis (ALS), as measured with the King's Clinical Staging System, and cognitive and behavioral change, measured with the Edinburgh Cognitive and Behavioural ALS Screen (ECAS). METHODS: A large multicenter observational cohort of 161 cross-sectional patients with ALS and 80 healthy matched controls were recruited across 3 research sites (Dublin, Edinburgh, and London). Participants were administered the ECAS and categorized into independent groups based on their King's clinical disease stage at time of testing. RESULTS: Significant differences were observed between patients and controls on all subtests of the ECAS except for visuospatial functioning. A significant cross-sectional effect was observed across disease stages for ALS-specific functions (executive, language, letter fluency) and ECAS total score but not for ALS-nonspecific functions (memory, visuospatial). Rates of ALS-specific impairment and behavioral change were also related to disease stage. The relationship between cognitive function and disease stage may be due to letter fluency impairment, whereas higher rates of all behavioral domains were seen in later King's stage. The presence of bulbar signs, but not site of onset, was significantly related to ALS-specific, ECAS total, and behavioral scores. CONCLUSION: ALS-specific cognitive deficits and behavioral impairment are more frequent with more severe disease stage. By end-stage disease, only a small percentage of patients are free of neuropsychological impairment. The presence of bulbar symptoms exaggerates the differences observed between disease stages. These findings suggest that cognitive and behavioral change should be incorporated into ALS diagnostic criteria and should be included in future staging systems. Lippincott Williams & Wilkins 2018-10-09 /pmc/articles/PMC6177274/ /pubmed/30209236 http://dx.doi.org/10.1212/WNL.0000000000006317 Text en Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Article Crockford, Christopher Newton, Judith Lonergan, Katie Chiwera, Theresa Booth, Tom Chandran, Siddharthan Colville, Shuna Heverin, Mark Mays, Iain Pal, Suvankar Pender, Niall Pinto-Grau, Marta Radakovic, Ratko Shaw, Christopher E. Stephenson, Laura Swingler, Robert Vajda, Alice Al-Chalabi, Ammar Hardiman, Orla Abrahams, Sharon ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS |
title | ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS |
title_full | ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS |
title_fullStr | ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS |
title_full_unstemmed | ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS |
title_short | ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS |
title_sort | als-specific cognitive and behavior changes associated with advancing disease stage in als |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6177274/ https://www.ncbi.nlm.nih.gov/pubmed/30209236 http://dx.doi.org/10.1212/WNL.0000000000006317 |
work_keys_str_mv | AT crockfordchristopher alsspecificcognitiveandbehaviorchangesassociatedwithadvancingdiseasestageinals AT newtonjudith alsspecificcognitiveandbehaviorchangesassociatedwithadvancingdiseasestageinals AT lonergankatie alsspecificcognitiveandbehaviorchangesassociatedwithadvancingdiseasestageinals AT chiweratheresa alsspecificcognitiveandbehaviorchangesassociatedwithadvancingdiseasestageinals AT boothtom alsspecificcognitiveandbehaviorchangesassociatedwithadvancingdiseasestageinals AT chandransiddharthan alsspecificcognitiveandbehaviorchangesassociatedwithadvancingdiseasestageinals AT colvilleshuna alsspecificcognitiveandbehaviorchangesassociatedwithadvancingdiseasestageinals AT heverinmark alsspecificcognitiveandbehaviorchangesassociatedwithadvancingdiseasestageinals AT maysiain alsspecificcognitiveandbehaviorchangesassociatedwithadvancingdiseasestageinals AT palsuvankar alsspecificcognitiveandbehaviorchangesassociatedwithadvancingdiseasestageinals AT penderniall alsspecificcognitiveandbehaviorchangesassociatedwithadvancingdiseasestageinals AT pintograumarta alsspecificcognitiveandbehaviorchangesassociatedwithadvancingdiseasestageinals AT radakovicratko alsspecificcognitiveandbehaviorchangesassociatedwithadvancingdiseasestageinals AT shawchristophere alsspecificcognitiveandbehaviorchangesassociatedwithadvancingdiseasestageinals AT stephensonlaura alsspecificcognitiveandbehaviorchangesassociatedwithadvancingdiseasestageinals AT swinglerrobert alsspecificcognitiveandbehaviorchangesassociatedwithadvancingdiseasestageinals AT vajdaalice alsspecificcognitiveandbehaviorchangesassociatedwithadvancingdiseasestageinals AT alchalabiammar alsspecificcognitiveandbehaviorchangesassociatedwithadvancingdiseasestageinals AT hardimanorla alsspecificcognitiveandbehaviorchangesassociatedwithadvancingdiseasestageinals AT abrahamssharon alsspecificcognitiveandbehaviorchangesassociatedwithadvancingdiseasestageinals |